AbbVie was founded in 2013, born out of the global biopharmaceutical powerhouse Abbott Laboratories, which had been a trusted name in healthcare for over a century. This spin-off was a strategic move to create a stand-alone company focused solely on AbbVie’s promising pipeline of innovative medicines.

AbbVie’s rise to fame began with the successful launch of its flagship drug, Humira, which was transferred from Abbott to AbbVie during the spin-off. Humira, a biologic used to treat autoimmune diseases, quickly became one of the world’s best-selling drugs, catapulting AbbVie into the limelight of the pharmaceutical industry.

AbbVie’s Current Net Worth (2025)

As of 2025, AbbVie’s market capitalization is approximately $220 billion, making it one of the world’s most valuable pharmaceutical companies. This figure reflects the company’s strong financial performance and its significant impact on the global biopharmaceutical industry.

Career

AbbVie was founded in 2013 as a spin-off from Abbott Laboratories. Since then, it has grown exponentially, focusing on the discovery, development, and marketing of advanced therapies for various diseases. The company’s portfolio includes blockbuster drugs like Humira, Imbruvica, and Skyrizi, which have significantly contributed to its success.

Other Ventures

In addition to its core pharmaceutical business, AbbVie has also ventured into other areas. It has established a venture capital fund, AbbVie Ventures, to invest in early-stage biotechnology companies. Furthermore, AbbVie has expanded its reach through strategic partnerships and collaborations with other pharmaceutical companies and academic institutions.

Assets

AbbVie’s assets are primarily intangible, consisting of intellectual property, including patents and trademarks, and goodwill. As of 2024, AbbVie’s total assets are valued at around $105 billion. The company’s most valuable assets are its drug pipelines and the commercial rights to its marketed products, particularly its immunology portfolio.

Annual Income

In 2024, AbbVie reported a total revenue of approximately $56 billion. The company’s annual income has seen consistent growth over the years, driven primarily by the strong performance of its immunology portfolio and the successful launch of new products. AbbVie’s net income in 2024 was around $24 billion, reflecting the company’s robust financial health.

Frequently Asked Questions about  Abbvie

Frequently Asked Questions: Abbvie Net Worth

1. What is Abbvie’s net worth?

Abbvie’s net worth is estimated to be around $140 billion.

2. How does Abbvie generate its revenue?

Abbvie generates revenue primarily through the sale of its pharmaceutical products. Its portfolio includes several blockbuster drugs like Humira, Imbruvica, and Rinvoq.

3. What is Abbvie’s most successful drug?

Humira, a drug used to treat autoimmune diseases, is Abbvie’s most successful drug. It generated over $20 billion in revenue in 2020 alone.

4. When was Abbvie founded?

Abbvie was founded in 2013 as a spin-off from Abbott Laboratories.

5. Where is Abbvie’s headquarters located?

Abbvie’s headquarters is located in North Chicago, Illinois, USA.

6. Who is the CEO of Abbvie?

Richard A. Gonzalez is the current CEO of Abbvie.

7. What is Abbvie’s market capitalization?

As of recent data, Abbvie’s market capitalization is around $170 billion.

8. Does Abbvie pay dividends to its shareholders?

Yes, Abbvie pays dividends to its shareholders. It has consistently increased its dividend payout since 2013.

9. What is Abbvie’s stock ticker symbol?

Abbvie’s stock ticker symbol is ABBV on the New York Stock Exchange (NYSE).

10. What are some of Abbvie’s key competitors?

Some of Abbvie’s key competitors include Amgen, Biogen, and Johnson & Johnson.